Aerie pharmaceuticals to announce third quarter 2015 financial results and host conference call on tuesday, november 3, 2015

Irvine, calif.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri), announced today that its third quarter 2015 financial results will be released after the market closes on tuesday, november 3, 2015. following the release, aerie will host a live conference call and webcast at 5:00 p.m. eastern time to discuss the company's financial results and provide a general business update. the live webcast and a replay may be accessed by visiting aerie's website at http://investors.aeriepharma.com. please connect to the company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. alternatively, please call (888) 734-0328 (u.s.) or (678) 894-3054 (international) to listen to the live conference call. the conference id number for the live call is 51129667. please dial in approximately 10 minutes prior to the call. telephone replay will be available approximately two hours after the call. to access the replay, please call (855) 859-2056 (u.s.) or (404) 537-3406 (international). the conference id number for the replay is 51129667. the telephone replay will be available until november 10, 2015. about aerie pharmaceuticals aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. aerie recently reported the successful results of its second phase 3 registration trial in the united states named rocket 2, where the primary efficacy endpoint was to demonstrate non-inferiority of iop lowering for rhopressa™ compared to timolol. rocket 3, a 12-month safety-only study, is currently in progress, and aerie has recently commenced a fourth phase 3 trial for rhopressa™, named rocket 4. aerie also completed in 2014 a phase 2b clinical trial in which roclatan™ met the primary efficacy endpoint, demonstrating the statistical superiority of roclatan™ to each of its components, and recently commenced the first phase 3 registration trial for roclatan™, named mercury 1. aerie also recently announced research collaborations with graybug, inc. and ramot at tel aviv university as it further builds its pipeline for future growth.
AERI Ratings Summary
AERI Quant Ranking